Curasight Company Description

Curasight A/S develops therapeutic and diagnostic solutions for the treatment of cancer.

It develops uTREAT therapeutic solutions, that are in Phase IIb clinical trials to treat glioblastoma, non-small cell lung cancers, neuroendocrine neoplasms, head and neck cancer, and pancreatic cancers.

The company is also developing uTRACE diagnostic solutions, which have completed Phase II clinical trial for the treatment of glioblastoma, prostate cancer, neuroendocrine neoplasms, head and neck cancer, breast cancer, and urinary bladder cancer; and is in Phase II clinical trials to treat non-small cell lung cancer.

Curasight A/S was incorporated in 2013 and is based in Copenhagen, Denmark.

Curasight A/S

Country	Denmark
Founded	2013
Industry	In Vitro and In Vivo Diagnostic Substances
Employees	4
CEO	Ulrich Krasilnikoff

Contact Details

Address: Ole Maaløes Vej 3 Copenhagen, 2200 Denmark
Phone	45 22 83 01 60
Website	curasight.com

Stock Details

Ticker Symbol	CURAS
Exchange	Nordic Growth Market
Fiscal Year	January - December
Reporting Currency	DKK
SIC Code	2835

Key Executives

Name	Position
Ulrich Krasilnikoff	Chief Executive Officer
Ulrich Krasilnikoff	Chief Financial Officer
Hanne Jensen	Chief Operating Officer